Another article accepted for publication!

The publication of Prof. Arnaud Scherpereel et al. titeled “Second- or third-line nivolumab versus nivolumab plus ipilimumab in malignant pleural mesothelioma patients: final results of the IFCT-1501 MAPS2 randomised Phase 2 trial”has been accepted for publication in “The Lancet Oncology, Online First”.

This Phase 2 trial was designed to investigate the usefulness of immunotherapy in the second line
setting for the management of malignant pleural mesothelioma. Immunotherapy via checkpoint
inhibitors is aimed to mobilize the patient’s own immune defenses against hostile tumor cells. This
mechanism of action differs from that of standard chemothdrapeutisc agents that act by directly
attacking tumor cells by inhibiting cell devision.

While the results of this Phase 2 study appear very promising, they still need to be confirmed by
larger-scale Phase 3 trials. This data will soon be available online.

We couldn’t be more thrilled about this latest success, and would like to encourage you too to
entrust your work to us, no matter where you currently are in the writing process! We take on
projects from conception right up to submission, as well as polishing near-complete work, as this
publishing success story proves!